Chinese regulator accepts NDA of BeiGene’s pamiparib in ovarian cancer
BeiGene said that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has…
Inozyme Pharma acquires Alexion’s ENPP1 gene deficiency program assets
Inozyme Pharma said that it has acquired Alexion Pharmaceuticals’ intellectual property and assets focused on ENPP1 gene deficiencies…
Chinese regulator accepts NDA of BeiGene’s pamiparib in ovarian cancer
BeiGene said that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted a new drug application (NDA) of pamiparib for the treatment of certain ovarian cancer patients. Pamiparib is an investigational inhibitor of PARP1 and PARP2 and its NDA is for patients having deleterious or suspected deleterious germline […]
Topcon Healthcare acquires Henson perimeter business of Elektron Eye Technology
Topcon Healthcare, a US ophthalmic device manufacturer, has acquired the Henson perimeter business of UK-based Elektron Eye Technology…
ChAdOx1 nCoV-19 vaccine : Russia’s R-Pharm signs deal with AstraZeneca
Russian pharma company R-Pharm has reportedly signed an agreement with AstraZeneca for manufacturing the ChAdOx1 nCoV-19 vaccine being…
ChAdOx1 nCoV-19 vaccine : Russia’s R-Pharm signs deal with AstraZeneca
Russian pharma company R-Pharm has reportedly signed an agreement with AstraZeneca for manufacturing the ChAdOx1 nCoV-19 vaccine being developed by the latter in collaboration with UK-based Oxford University. The entire world is pinning hopes on the ChAdOx1 nCoV-19 vaccine candidate, which reportedly seems to be the most probable to become the first vaccine against the […]
Ascentage Pharma gets FDA ODD for APG-2575 in Waldenström macroglobulinemia
Ascentage Pharma has been granted orphan drug designation (ODD) for its Bcl-2 inhibitor APG-2575 from the US Food…
Blueprint Medicines strikes $1.7bn worth deal with Roche for pralsetinib
Swiss pharma giant Roche and US precision therapy company Blueprint Medicines have entered into a worldwide licensing and…
Galera Therapeutics enrolls patients for pancreatic cancer trial of GC4419
Galera Therapeutics said that it has wrapped up enrollment of patients for its phase 1b/2a safety and anti-cancer…
BNT162b1 and BNT162b2 Covid-19 vaccine candidates get FDA fast track status
Pfizer and BioNTech said that BNT162b1 and BNT162b2, two vaccine candidates developed to give protection against the SARS-CoV-2…